WO2000027370A1 - Controlled release formulation for water soluble drugs - Google Patents
Controlled release formulation for water soluble drugs Download PDFInfo
- Publication number
- WO2000027370A1 WO2000027370A1 PCT/US1999/025604 US9925604W WO0027370A1 WO 2000027370 A1 WO2000027370 A1 WO 2000027370A1 US 9925604 W US9925604 W US 9925604W WO 0027370 A1 WO0027370 A1 WO 0027370A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diltiazem
- layer
- water soluble
- formulation
- once
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Definitions
- the present invention relates to controlled release unit dose formulations of water soluble drugs in general which are exemplified by diltiazem hydrochloride (diltiazem) .
- diltiazem diltiazem hydrochloride
- Diltiazem is sold commercially in extended release pharmaceutical dosage forms in order to maintain a therapeutic serum level of diltiazem and to minimize the effects of missed doses of drugs caused by a lack of patient compliance.
- the minimum therapeutic plasma diltiazem concentrations are in the range of 50 to 200 ng/ml.
- Cardizem® CD is described as a once-a-day extended release capsule containing diltiazem and fumaric acid.
- the formulation disclosed in that patent is the formulation for Cardizem® CD.
- the formulation for Cardizem® CD is identified in the file history of U.S. 5,286,497 as having a "stair-step release profile" which has a rapid release bead and an extended release bead.
- U.S. 5,567,441 also discloses a formulation of diltiazem which is bioequivalent to Cardizem CD but has a different release profile in hydrochloric acid. That formulation exhibits a slower in vitro release profile in 0. IN hydrochloric acid than the slow release bead of the present invention but exhibits substantially the same in vivo release profile .
- U.S. 5,229,135 and in U.S. 5,529,791 once-a-day formulations are described that are based on a single pellet which is prepared with an active core which is coated with diltiazem and an inner and outer membrane.
- Other diltiazem formulations are disclosed in U.S. 4,721,619; U.S. 4,894,240; U.S. 5,002,776; U.S. 5,364,620; 4,891,230; U.S. 4,917,899; U.S. 5,288,505; and U.S. 5,336,504.
- the present invention provides novel water soluble pharmaceutical formulations which are two- pellet based capsule formulations.
- the diltiazem formulations made according to the present invention do not have a "stair-step release profile” but do provide a "two- peak pharmacokinetic profile” .
- the diltiazem formulations of the present invention does not require the presence of fumaric acid or any other organic acid in the core.
- the present invention also provides a means for varying the release rates of water soluble to allow for faster in vitro release of the drug.
- the present invention is directed to a once-a-day controlled release water soluble pharmaceutical formulation which comprises:
- polymeric enteric coated pellets comprising a polymer membrane coated core which comprises a biologically inert core which is coated with a first layer which consists essentially of a water soluble drug and a polymeric binder; and a second layer which comprises a membrane comprising a polymeric enteric coating material; and
- delayed pulse polymeric membrane coated pellets comprising a polymeric membrane coated core which comprises a biologically inert core which is coated with a combined first layer which consists essentially of a water soluble drug and a polymeric binder and a second layer which comprises a polymeric membrane and an alkaline earth metal stearate said second layer being capable of substantially maintaining its integrity in the varying pH conditions of the gastrointestinal tract and being permeable to said water soluble drug; and
- the present invention also provides a dosage form of diltiazem which exhibits in 0. IN HC1 , a release rate profile which is initially a relatively slow, zero order release rate that continues for up to about 12-14 hours. Thereafter, there is a sharp increase in the rate of release which can be characterized as a delayed pulse. It is surprising and unexpected that the combined zero order-delayed pulse in vitro release characteristics of the diltiazem dosage form of the present invention provides substantially the same in vivo "two peak" plasma levels of diltiazem which is provided by a commercial formulation which exhibits in vitro a stair-step type of release profile.
- FIG. 1 is a graph which shows the in vitro dissolution rate of diltiazem delayed pulse membrane coated core pellets prepared according to Example 1 of the present invention in 0. IN HCl using a USP Type II apparatus at 37°C and lOOrpm and simulated intestinal fluid (pH 7.5) using a USP Type II apparatus at 37°C and 75rpm .
- FIG. 2 is a graph which shows the in vitro dissolution rate of diltiazem delayed pulse membrane coated core pellets prepared according to Example 2 of the present invention in 0. IN HCl and simulated intestinal fluid (pH 7.5) using a USP Type II apparatus at 37°C and lOOrpm.
- FIG. 3 is a graph which shows the in vitro dissolution rate of diltiazem delayed pulse membrane coated core pellets prepared according to Comparative Example 3 of the present application in 0. IN HCl and simulated intestinal fluid (pH 7.5) using a USP Type II apparatus at 37° C and lOOrpm.
- FIG. 4 is a graph which shows a plot of the mean plasma diltiazem concentrations versus time, of a diltiazem formulation prepared according to Example 1 with the points shown by circles and a plot of the mean diltiazem concentrations of Cardizem CD where the reference points are shown by squares.
- the once-a-day, controlled release formulation for water soluble drugs provides an alternative to prior art formulations for once-a-day dosing of drugs that are to be maintained at a steady state level in the blood plasma.
- Suitable water soluble drugs which are useful in the dosage formulation of the present invention include diltiazem hydrochloride, verapamil hydrochloride, bupropion hydrochloride, metformin hydrochloride, propranolol hydrochloride, dextromethorphan hydrobromide , diphenhydramine hydrochloride, disopyramide hydrochloride, tramadol, fluoxetine hydrochloride, paroxetine hydrochloride, pentoxifylline hydrochloride and the like.
- Both the enteric polymer membrane coated pellet and the delayed pulse polymer membrane coated pellet are based on an active core which contains the diltiazem hydrochloride.
- the core is made by coating a biologically inactive core component such as nonpareil sugar particles i.e., sugar spheres NF, starch granules, clay particles or other material on which may be deposited a coating of diltiazem hydrochloride in combination with a polymeric binder which comprises from 5 to 10wt% (based on the combined weight of the binder and the diltiazem) .
- the binder can be any pharmaceutically acceptable binding agent known to the art such as ethylcellulose, polyvinylpyrrolidone, hydroxypropyl methylcellulose and hydroxypropylcellulose .
- the binder is applied using conventional solvents which are removed from the product during processing.
- the active core component is provided with an enteric coating which is a polymeric enteric coating material to form a rapid release bead.
- enteric coatings are "pH dependent" which describes the well known effect of an enteric coating which prevents release of the dosage form in the low pH conditions of the stomach but permits release in the higher pH conditions of the small intestine.
- the enteric coating will comprise from 4 to 15% preferably from 5 to 11% by weight based on the combined weight of the active core component and the total weight of the coating.
- the enteric coating polymer may be selected from the group consisting of shellac, methacrylic acid copoly ers, (Eudragit S or L) cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate , hydroxypropylmethylcellulose acetate succinate, cellulose acetate trimellitate and polyvinyl acetate phthalate.
- USP/NFXXII which dissolves at a pH above about 7.0 is preferred.
- the thickness of the coating is selected to provide the desired release rate depending on the thickness of the coating and the particular coating.
- a commercially available copolymer is
- Eudragit S100 which is based on methacrylic acid and methyl methacrylate and has a weight average molecular weight of about 150,000.
- Other auxiliary coating aids such as a minor amount (l-5wt% based on the active core component and the total weight of the final coating) of a plasticizer such as acetyltributyl citrate, triacetin, acetylated monoglyceride, rape oil, olive oil, sesame oil, acetyltriethylcitrate, glycerin sorbitol, diethyloxalate, diethylmalate, diethylfumarate, dibutylsuccinate, diethylmalonate, dioctylphthalate, dibutylsebacate, triethylcitrate, tributylcitrate, glyceroltributyrate, polyethyleneglycol (molecular weight of from 380 to 420) , propy
- the antisticking agents can be used alone or in combination.
- the antisticking agent may be added in an amount which is equivalent to 0.3 to 1.0:1.0 by weight of the methacrylic acid copolymer. These amounts may be varied to obtain the particular release rate that is desired. These components may be added to the methacrylic acid copolymer in combination with appropriate solvents.
- the delayed pulse polymeric coated pellet contains an active core which is coated with a polymeric material which will substantially maintain its integrity in the varying pH conditions of the gastrointestinal tract but is permeable to diltiazem.
- the delayed pulse polymeric pellet is designed to release not less than 65% and preferably not less than 75% of diltiazem in vitro about 18 hours after the dosage form of the invention is placed in 0. IN HCl.
- the rate of release for the delayed pulse pellet is sharply increased, i.e. about 3 to 5 times, as compared to the in vitro rate of release of the enteric coated diltiazem pellets of the
- the delayed pulse pellets are made by coating the active core component with 15 is 35wt% and preferably from 15 to 30wt% (based on the combined weight of the active core and the total weight of the final coating) of a polymer such as ethyl cellulose, cellulose acetate, cellulose acetate butyrate, or an acrylic copolymer which when used in a sufficient amount will cause the delayed pulse pellet to begin to release diltiazem 10 to 12 hours after the ingestion of the dosage form of the invention.
- Materials such as Eudragit RS 30D; RS 100; NE 30D; RL 30D or RL 100 may be used to prepare the delayed pulse pellet.
- a preferred material is an acrylate copolymer which has a permeability which is independent of pH.
- Such a preterred acrylate copolymer is commercially available as Eudragit RS30D which is available as a 30wt% aqueous dispersion of copolymers of acrylic and methacrylic acid esters, having a number average molecular weight of 150,000 with a low content of quaternary ammonium groups .
- auxiliary coating aids such as a minor amount (2-7wt% based on the active core component and the total weight of the final coating) of a plasticizer such as acetyltributyl citrate, triacetin, acetylated monoglyceride, rape oil, olive oil, sesame oil, acetyltriethylcitrate, glycerin sorbitol, diethyloxalate, diethylmalate, diethylfumarate, dibutylsuccinate, diethylmalonate, dioctylphthalate, dibutylsebacate, triethylcitrate, tributylcitrate, glyceroltributyrate, polyethyleneglycol (molecular weight of from 380 to 420) , propylene glycol and mixtures thereof in combination with an antisticking agent which comprises a alkaline earth stearate such as magnesium or calcium stearate alone or in combination with
- the controlled release diltiazem formulation of the invention will preferably have a dissolution release rate in simulated intestinal fluid (pH7.5) in a USP XXII Type II apparatus at 37°C and 75rpm which substantially corresponds to the following: a) from 20 to 50wt% and preferably from 25 to 45wt% of total diltiazem is released after 2 hours; b) from 30 to 65wt% and preferably from 35 to 55wt% of total diltiazem is released after 12 hours; c) from 60 to 95wt% and preferably from 65 to 90wt% of total diltiazem is released after 18 hours; d) not less than 75wt% and preferably not less than
- the enteric coated diltiazem beads of the invention will preferably have a dissolution release rate in hydrochloric acid, 0.
- the delayed pulse diltiazem beads of the invention will preferably have a dissolution release rate in hydrochloric acid, 0.1N, in a USP XXII Type II apparatus at 37°C and lOOrpm which substantially corresponds to the following: a) from 0 to 15wt% and preferably not more than 10%% of total diltiazem is released after 12 hours; b) from 65 to 90wt% of total diltiazem and preferably 70 to 85wt% is released after 18 hours; c) not less than 80wt% of total diltiazem is released after 24 hours.
- enteric polymer pellets of the invention and the delayed pulse polymer membrane coated pellets may be placed in soft or hard gelatin capsules or in other dosage forms such as tablets which contain a cushioning agent to prevent damage to the pellets or the polyethylene glycol based dosage formulation which is disclosed in U.S. 5,458,888, which is incorporated by reference.
- the dosage form will contain from about 20 to 50wt% and preferably about 40wt% of the enteric polymer membrane coated pellets and from about 50 to 80wt% and preferably about 60wt% of the delayed pulse polymer coated pellets.
- the coating suspension is sprayed onto the sugar spheres in a fluidized bed coater under the following conditions: product temp. 20-35°C; atomization pressure 2-4 bars; air volume 700-1800 m 3 /L and a pump rate of 300-
- diltiazem active pellets (A) are then coated with the enteric polymer to form enteric polymer membrane coated diltiazem rapid release pellets as follows: diltiazem HCl Active pellets (A) 93.0wt% 98.58kg methacrylic acid copolymer 4.725t% 5.01kg (Eudragit S100) acetyltributvl citrate 0.70wt% 0.74kg talc, USP 1.575wt% 1.67kg isopropyl alcohol, USP 111.0kg purified water, USP 3. I4k
- the acetyl tributyl citrate is dissolved in the isopropyl alcohol in a stainless steel tank while homogenizing.
- the Eudragit S-100 is added to the acetyltributyl citrate/isopropyl alcohol solution until it completely dissolves.
- Purified water is added to the polymer solution to provide a clear solution.
- the talc is dispersed in the solution while mixing until a uniform coating suspension is formed. The solution is continuously stirred throughout the coating process to prevent sedimentation of the talc.
- Extended release or delayed pulse diltiazem pellets are prepared using the following coating suspension:
- the diltiazem active pellets are loaded into a fluidized bed coater at an inlet temperature of 50°C.
- the pellets are preheated at a temperature of 50°C for 3 minutes.
- product temperature first hour; 35-40°C; thereafter 32-35°C; atomization pressure; 3-4 bar; pump rate; first hour: 300-600g/min, then 600- 1500g/min.
- the resultant pellets are mixed with the rapid release beads in a ratio of 4:6 based on the content of diltiazem HCl. Then, the blended pellets are encapsulated into a hard gelatin capsule to manufacture the diltiazem HCl ER capsules 300mg.
- Example 2 provides an alternative delayed pulse bead formula which is made using the procedure of Example 1 without magnesium stearate:
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000580601A JP4536929B2 (en) | 1998-11-06 | 1999-11-01 | Controlled release formulation of water-soluble drugs |
AU15186/00A AU755287B2 (en) | 1998-11-06 | 1999-11-01 | Controlled release formulation for water soluble drugs |
CA002349696A CA2349696C (en) | 1998-11-06 | 1999-11-01 | Controlled release formulation for water soluble drugs |
EP99957493A EP1124543A4 (en) | 1998-11-06 | 1999-11-01 | Controlled release formulation for water soluble drugs |
NZ511448A NZ511448A (en) | 1998-11-06 | 1999-11-01 | A dosage form of diltiazem that exhibits a release rate profile corresponding to a "two peak" plasma level profile in vivo |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/187,319 | 1998-11-06 | ||
US09/187,319 US6270805B1 (en) | 1998-11-06 | 1998-11-06 | Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000027370A1 true WO2000027370A1 (en) | 2000-05-18 |
Family
ID=22688495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/025604 WO2000027370A1 (en) | 1998-11-06 | 1999-11-01 | Controlled release formulation for water soluble drugs |
Country Status (7)
Country | Link |
---|---|
US (1) | US6270805B1 (en) |
EP (1) | EP1124543A4 (en) |
JP (1) | JP4536929B2 (en) |
AU (1) | AU755287B2 (en) |
CA (1) | CA2349696C (en) |
NZ (1) | NZ511448A (en) |
WO (1) | WO2000027370A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002028376A3 (en) * | 2000-10-03 | 2003-03-06 | Mehta Atul M | Chrono delivery formulations and method of use thereof |
EP1357898A2 (en) * | 2001-02-08 | 2003-11-05 | ANDRX Pharmaceuticals, Inc. | Improved controlled release oral dosage form |
US6984402B2 (en) | 2000-10-03 | 2006-01-10 | Elite Laboratories, Inc. | Chrono delivery formulations and method of treating atrial fibrillation |
US7771750B2 (en) | 1999-02-26 | 2010-08-10 | Andrx Pharmaceuticals, Llc | Controlled release oral dosage form |
US8377977B2 (en) | 2004-08-13 | 2013-02-19 | Boehringer Ingelheim International Gmbh | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
US8679533B2 (en) | 2002-07-25 | 2014-03-25 | Pharmacia Corporation | Pramipexole once-daily dosage form |
US8715728B2 (en) | 2004-08-13 | 2014-05-06 | Boehringer Ingelheim International Gmbh | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6733789B1 (en) | 1999-01-21 | 2004-05-11 | Biovail Laboratories, Inc. | Multiparticulate bisoprolol formulation |
EP1064938A1 (en) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
US20040185099A1 (en) * | 2000-01-20 | 2004-09-23 | Biovail Laboratories, Inc. | Multiparticulate bisoprolol formulation |
US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
US6866866B1 (en) * | 2000-11-03 | 2005-03-15 | Andrx Labs, Llc | Controlled release metformin compositions |
US6790459B1 (en) * | 2000-11-03 | 2004-09-14 | Andrx Labs, Llc | Methods for treating diabetes via administration of controlled release metformin |
US20060034922A1 (en) * | 2000-11-03 | 2006-02-16 | Andrx Labs, Llc | Controlled release metformin compositions |
US20040253312A1 (en) * | 2001-09-28 | 2004-12-16 | Sowden Harry S. | Immediate release dosage form comprising shell having openings therein |
US20030228368A1 (en) * | 2001-09-28 | 2003-12-11 | David Wynn | Edible solid composition and dosage form |
MXPA04002979A (en) | 2001-09-28 | 2005-06-20 | Johnson & Johnson | Modified release dosage forms. |
US6837696B2 (en) * | 2001-09-28 | 2005-01-04 | Mcneil-Ppc, Inc. | Apparatus for manufacturing dosage forms |
US7838026B2 (en) | 2001-09-28 | 2010-11-23 | Mcneil-Ppc, Inc. | Burst-release polymer composition and dosage forms comprising the same |
US20040146559A1 (en) * | 2002-09-28 | 2004-07-29 | Sowden Harry S. | Dosage forms having an inner core and outer shell with different shapes |
US7122143B2 (en) | 2001-09-28 | 2006-10-17 | Mcneil-Ppc, Inc. | Methods for manufacturing dosage forms |
US20030118652A1 (en) * | 2001-11-15 | 2003-06-26 | John Kelly | Methods and compositions for use of (S)-bisoprolol |
US20030091633A1 (en) * | 2001-11-15 | 2003-05-15 | John Kelly | Methods and compositions for use of (S)-bisoprolol |
US20050182056A9 (en) * | 2002-02-21 | 2005-08-18 | Seth Pawan | Modified release formulations of at least one form of tramadol |
US8128957B1 (en) | 2002-02-21 | 2012-03-06 | Valeant International (Barbados) Srl | Modified release compositions of at least one form of tramadol |
US7022342B2 (en) * | 2002-03-28 | 2006-04-04 | Andrx Corporation, Inc. | Controlled release oral dosage form of beta-adrenergic blocking agents |
WO2003099214A2 (en) * | 2002-05-23 | 2003-12-04 | Andrx Corporation | Biguanide formulations |
KR20050086409A (en) * | 2002-08-15 | 2005-08-30 | 유로-셀티크 소시에떼 아노뉨 | Pharmaceutical compositions |
US7807197B2 (en) * | 2002-09-28 | 2010-10-05 | Mcneil-Ppc, Inc. | Composite dosage forms having an inlaid portion |
US6893660B2 (en) * | 2002-11-21 | 2005-05-17 | Andrx Pharmaceuticals, Inc. | Stable pharmaceutical compositions without a stabilizer |
US20040131672A1 (en) * | 2003-01-07 | 2004-07-08 | Nilobon Podhipleux | Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties |
US20040208932A1 (en) * | 2003-04-17 | 2004-10-21 | Ramachandran Thembalath | Stabilized paroxetine hydrochloride formulation |
EP1648407A4 (en) | 2003-07-21 | 2011-08-31 | Middlebrook Pharmaceuticals Inc | Antibiotic product, use and formulation thereof |
EP1648415A4 (en) | 2003-07-21 | 2011-11-16 | Middlebrook Pharmaceuticals Inc | Antibiotic product, use and formulation thereof |
JP2006528185A (en) | 2003-07-21 | 2006-12-14 | アドバンシス ファーマスーティカル コーポレイション | Antibiotic preparations, their use and preparation |
MEP3608A (en) * | 2003-08-08 | 2011-05-10 | Biovail Lab Int Srl | Modified-release tablet of bupropion hydrochloride |
JP2007502296A (en) | 2003-08-11 | 2007-02-08 | アドバンシス ファーマスーティカル コーポレイション | Robust pellet |
AU2004264356B2 (en) | 2003-08-12 | 2011-01-27 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
EP1658034A4 (en) * | 2003-08-29 | 2011-06-22 | Middlebrook Pharmaceuticals Inc | Antibiotic product, use and formulation thereof |
WO2005027877A1 (en) | 2003-09-15 | 2005-03-31 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
US20050069590A1 (en) * | 2003-09-30 | 2005-03-31 | Buehler Gail K. | Stable suspensions for medicinal dosages |
US20050074514A1 (en) * | 2003-10-02 | 2005-04-07 | Anderson Oliver B. | Zero cycle molding systems, methods and apparatuses for manufacturing dosage forms |
ATE493981T1 (en) | 2003-11-04 | 2011-01-15 | Supernus Pharmaceuticals Inc | ONCE DAILY DOSAGE FORMS OF TROSPIUM |
US20050142203A1 (en) * | 2003-12-30 | 2005-06-30 | Grant Heinicke | Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same |
US8067029B2 (en) | 2004-01-13 | 2011-11-29 | Mcneil-Ppc, Inc. | Rapidly disintegrating gelatinous coated tablets |
US7879354B2 (en) * | 2004-01-13 | 2011-02-01 | Mcneil-Ppc, Inc. | Rapidly disintegrating gelatinous coated tablets |
US20050196442A1 (en) * | 2004-03-05 | 2005-09-08 | Huang Hai Y. | Polymeric compositions and dosage forms comprising the same |
US20050196447A1 (en) * | 2004-03-05 | 2005-09-08 | Huang Hai Y. | Polymeric compositions and dosage forms comprising the same |
US20050196448A1 (en) * | 2004-03-05 | 2005-09-08 | Hai Yong Huang | Polymeric compositions and dosage forms comprising the same |
US20050196446A1 (en) * | 2004-03-05 | 2005-09-08 | Huang Hai Y. | Polymeric compositions and dosage forms comprising the same |
DE602005003343T2 (en) * | 2004-04-12 | 2008-09-11 | Pfizer Products Inc., Groton | MEDICINAL PRODUCTS WITH HIDDEN TASTE IN BREAKING MULTIPARTICLES |
CA2572292A1 (en) | 2004-07-02 | 2006-02-09 | Advancis Pharmaceutical Corporation | Tablet for pulsed delivery |
US20060087051A1 (en) * | 2004-10-27 | 2006-04-27 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US8383159B2 (en) * | 2004-10-27 | 2013-02-26 | Mcneil-Ppc, Inc. | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US20060088587A1 (en) * | 2004-10-27 | 2006-04-27 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US20060088586A1 (en) * | 2004-10-27 | 2006-04-27 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US20070281022A1 (en) * | 2004-10-27 | 2007-12-06 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US20060088593A1 (en) * | 2004-10-27 | 2006-04-27 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US20070190133A1 (en) * | 2004-10-27 | 2007-08-16 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US8673352B2 (en) | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
CA2578626C (en) | 2005-06-27 | 2011-07-19 | Biovail Laboratories International S.R.L. | Modified-release formulations of a bupropion salt |
US8778395B2 (en) * | 2005-08-11 | 2014-07-15 | Andrx Labs, Llc | Diltiazem controlled release formulation and method of manufacture |
US20070077300A1 (en) * | 2005-09-30 | 2007-04-05 | Wynn David W | Oral compositions containing a salivation inducing agent |
US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
US7674479B2 (en) * | 2006-07-25 | 2010-03-09 | Intelgenx Corp. | Sustained-release bupropion and bupropion/mecamylamine tablets |
US8703191B2 (en) * | 2006-07-25 | 2014-04-22 | Intelgenx Corp. | Controlled-release pharmaceutical tablets |
CN101563074B (en) * | 2006-10-20 | 2012-11-07 | 麦克内尔-Ppc股份有限公司 | Acetaminophen / ibuprofen combinations |
US10357462B2 (en) * | 2006-11-30 | 2019-07-23 | Ben Research, Inc. | Multiparticulates of spray-coated drug and polymer on a meltable core |
US11116728B2 (en) | 2006-11-30 | 2021-09-14 | Bend Research, Inc. | Multiparticulates of spray-coated drug and polymer on a meltable core |
US20080317678A1 (en) * | 2007-06-22 | 2008-12-25 | Szymczak Christopher E | Laser Marked Dosage Forms |
US20080317677A1 (en) * | 2007-06-22 | 2008-12-25 | Szymczak Christopher E | Laser Marked Dosage Forms |
US20090060983A1 (en) * | 2007-08-30 | 2009-03-05 | Bunick Frank J | Method And Composition For Making An Orally Disintegrating Dosage Form |
WO2009058798A2 (en) * | 2007-10-31 | 2009-05-07 | Mcneil-Ppc, Inc. | Orally disintegrated dosage form |
BRPI0821735A2 (en) * | 2007-12-21 | 2015-06-16 | Mcneil Ppc Inc | Tablet Manufacturing |
US20110020439A1 (en) * | 2008-03-24 | 2011-01-27 | Shrenik Annasaheb Kole | Delayed release compositions of duloxetine |
BRPI0915411A2 (en) * | 2008-06-26 | 2015-11-03 | Mcneil Ppc Inc | coated particles containing pharmaceutically active agents |
US20110070286A1 (en) * | 2009-09-24 | 2011-03-24 | Andreas Hugerth | Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process |
US8858210B2 (en) | 2009-09-24 | 2014-10-14 | Mcneil-Ppc, Inc. | Manufacture of variable density dosage forms utilizing radiofrequency energy |
US9610224B2 (en) * | 2009-09-24 | 2017-04-04 | Johnson & Johnson Consumer Inc. | Manufacture of tablet in a die utilizing powder blend containing water-containing material |
US8313768B2 (en) | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
US20110136815A1 (en) * | 2009-12-08 | 2011-06-09 | Horst Zerbe | Solid oral film dosage forms and methods for making same |
US10610528B2 (en) | 2009-12-08 | 2020-04-07 | Intelgenx Corp. | Solid oral film dosage forms and methods for making same |
US9233491B2 (en) | 2012-05-01 | 2016-01-12 | Johnson & Johnson Consumer Inc. | Machine for production of solid dosage forms |
US9511028B2 (en) | 2012-05-01 | 2016-12-06 | Johnson & Johnson Consumer Inc. | Orally disintegrating tablet |
US9445971B2 (en) | 2012-05-01 | 2016-09-20 | Johnson & Johnson Consumer Inc. | Method of manufacturing solid dosage form |
JP6150564B2 (en) * | 2013-03-08 | 2017-06-21 | 杏林製薬株式会社 | Orally rapidly disintegrating tablets |
BR112016015944A8 (en) | 2014-01-10 | 2020-06-09 | Johnson & Johnson Consumer Inc | process to produce tablet, which uses radiofrequency and coated particles dissipating energy |
US10736905B1 (en) | 2016-09-09 | 2020-08-11 | Shahin Fatholahi | Nefopam dosage forms and methods of treatment |
US10493026B2 (en) | 2017-03-20 | 2019-12-03 | Johnson & Johnson Consumer Inc. | Process for making tablet using radiofrequency and lossy coated particles |
US11446311B2 (en) | 2017-09-08 | 2022-09-20 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
US10736874B1 (en) | 2017-09-08 | 2020-08-11 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5229135A (en) * | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
US5529791A (en) * | 1991-06-26 | 1996-06-25 | Galephar P.R., Inc., Ltd. | Extended release form of diltiazem |
US5567441A (en) * | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4894240A (en) | 1983-12-22 | 1990-01-16 | Elan Corporation Plc | Controlled absorption diltiazem formulation for once-daily administration |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
JP2558396B2 (en) | 1990-06-28 | 1996-11-27 | 田辺製薬株式会社 | Controlled release formulation |
US5286497A (en) | 1991-05-20 | 1994-02-15 | Carderm Capital L.P. | Diltiazem formulation |
US5252337A (en) * | 1991-06-25 | 1993-10-12 | Eurand America, Inc. | Controlled release calcium channel blocker microcapsules |
US5260068A (en) | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
US5834024A (en) | 1995-01-05 | 1998-11-10 | Fh Faulding & Co. Limited | Controlled absorption diltiazem pharmaceutical formulation |
US5830503A (en) * | 1996-06-21 | 1998-11-03 | Andrx Pharmaceuticals, Inc. | Enteric coated diltiazem once-a-day formulation |
US5914134A (en) * | 1997-01-27 | 1999-06-22 | Wockhardt Europe Limited | Process for the pulsatile delivery of diltiazem HCL and product produced thereby |
US5840329A (en) * | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
-
1998
- 1998-11-06 US US09/187,319 patent/US6270805B1/en not_active Expired - Lifetime
-
1999
- 1999-11-01 CA CA002349696A patent/CA2349696C/en not_active Expired - Lifetime
- 1999-11-01 NZ NZ511448A patent/NZ511448A/en not_active IP Right Cessation
- 1999-11-01 JP JP2000580601A patent/JP4536929B2/en not_active Expired - Fee Related
- 1999-11-01 AU AU15186/00A patent/AU755287B2/en not_active Ceased
- 1999-11-01 WO PCT/US1999/025604 patent/WO2000027370A1/en not_active Application Discontinuation
- 1999-11-01 EP EP99957493A patent/EP1124543A4/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5529791A (en) * | 1991-06-26 | 1996-06-25 | Galephar P.R., Inc., Ltd. | Extended release form of diltiazem |
US5229135A (en) * | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
US5567441A (en) * | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
Non-Patent Citations (1)
Title |
---|
See also references of EP1124543A4 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7771750B2 (en) | 1999-02-26 | 2010-08-10 | Andrx Pharmaceuticals, Llc | Controlled release oral dosage form |
US8545880B2 (en) | 1999-02-26 | 2013-10-01 | Andrx Pharmaceuticals, Llc | Controlled release oral dosage form |
US8747898B2 (en) | 1999-02-26 | 2014-06-10 | Andrx Pharmaceuticals, Llc | Controlled release oral dosage form |
WO2002028376A3 (en) * | 2000-10-03 | 2003-03-06 | Mehta Atul M | Chrono delivery formulations and method of use thereof |
US6926909B2 (en) | 2000-10-03 | 2005-08-09 | Elite Laboratories, Inc. | Chrono delivery formulations and method of use thereof |
US6984402B2 (en) | 2000-10-03 | 2006-01-10 | Elite Laboratories, Inc. | Chrono delivery formulations and method of treating atrial fibrillation |
EP1357898A2 (en) * | 2001-02-08 | 2003-11-05 | ANDRX Pharmaceuticals, Inc. | Improved controlled release oral dosage form |
EP1357898A4 (en) * | 2001-02-08 | 2005-07-13 | Andrx Pharmaceuticals Inc | Improved controlled release oral dosage form |
US8679533B2 (en) | 2002-07-25 | 2014-03-25 | Pharmacia Corporation | Pramipexole once-daily dosage form |
US8377977B2 (en) | 2004-08-13 | 2013-02-19 | Boehringer Ingelheim International Gmbh | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
US8715728B2 (en) | 2004-08-13 | 2014-05-06 | Boehringer Ingelheim International Gmbh | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
Also Published As
Publication number | Publication date |
---|---|
AU1518600A (en) | 2000-05-29 |
US6270805B1 (en) | 2001-08-07 |
CA2349696A1 (en) | 2000-05-18 |
JP4536929B2 (en) | 2010-09-01 |
EP1124543A4 (en) | 2004-03-31 |
JP2002529401A (en) | 2002-09-10 |
EP1124543A1 (en) | 2001-08-22 |
CA2349696C (en) | 2010-03-09 |
NZ511448A (en) | 2003-06-30 |
AU755287B2 (en) | 2002-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU755287B2 (en) | Controlled release formulation for water soluble drugs | |
AU697164B2 (en) | Diltiazem controlled release formulation | |
EP1748764B1 (en) | An amine drug-containing slow-release granule preparation based on particles with a coating layer and the corresponding method of production | |
JP3015105B2 (en) | Powder coated oral dosage form | |
AU737121B2 (en) | Tramadol multiple unit formulations | |
US5478573A (en) | Delayed, sustained-release propranolol pharmaceutical preparation | |
AU757915B2 (en) | Controlled release bupropion formulation | |
SK656388A3 (en) | Pharmaceutical preparation consisting of granules with tetracycline compound | |
CS244909B2 (en) | Production method of retarded form of bromohexine | |
JP2002523443A (en) | Omeprazole preparation | |
MXPA03009588A (en) | A novel coating for a sustained release pharmaceutical composition. | |
IE861139L (en) | Timed disintergration capsules | |
AU6699100A (en) | Oral pharmaceutical forms of administration with a delayed action | |
SK285152B6 (en) | Enteric coated pharmaceutical composition a method for its preparation | |
RU2372893C2 (en) | Coated compound containing pharmaceutical agent | |
US7138143B1 (en) | Coated preparation soluble in the lower digestive tract | |
IE900862L (en) | A drug-release controlling coating material for long acting¹formulations | |
WO1997033574A1 (en) | Sustained-release metal valproate tablets | |
EP0929301A2 (en) | Controlled release dosage form of r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo 2.2.2]oct-3-yl)acetonitrile monohydrochloride | |
CA2409721A1 (en) | A coating composition for facilitating controlled release | |
WO2005044235A1 (en) | Controlled release formulation of tamsulosin hydrochloride and preparation process thereof | |
WO2010037849A1 (en) | Duloxetine enteric pellets | |
CA2685214A1 (en) | Improved controlled release oral dosage form | |
NZ510231A (en) | Omeprazole formulation comprising an alkaline core and an enteric coating | |
KR20070020977A (en) | The pharmaceutical oral formulations comprising pantoprazol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 15186 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 15186/00 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 580601 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 511448 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2349696 Country of ref document: CA Ref country code: CA Ref document number: 2349696 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999957493 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999957493 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 15186/00 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999957493 Country of ref document: EP |